Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that eyelash loss, facial papules, and body hair involvement were linked to severe frontal fibrosing alopecia, and antiandrogens were the most effective treatment.

This study suggests that folliculin, mutated in Birt–Hogg–Dubé syndrome, and its partner FNIP1 may play a role in energy and nutrient sensing through the AMPK and mTOR pathways.

This review discusses the potential usefulness and safety profile of oral antiandrogens for treating frontal fibrosing alopecia, noting possible benefits but acknowledges that finasteride's efficacy remains uncertain.

This study found that Tofacitinib effectively improved hair regrowth in patients with Alopecia Areata, with most participants showing a significant change in their Severity of Alopecia Tool scores.

Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.

In this study, researchers analyzed trichoscopy findings in black patients with FFA to aid in precise diagnosis and treatment, highlighting the importance of understanding disease characteristics to improve hair care in this group.

This study found that a fenugreek seed extract nanoformulation significantly improved hair growth and length in Wistar rats with alopecia, outperforming conventional gels and oils, suggesting enhanced skin penetration and reduced side effects.

In this study, tofacitinib treatment significantly reduced hair loss on the head and body, as well as nail involvement, in patients with alopecia areata over 18 months, with minimal side effects reported.

This study reported that tofacitinib may be a promising treatment for alopecia areata in adolescents, showing significant hair regrowth with mild adverse effects in a retrospective review.

This study observed that follicular unit extraction hair transplant initiated noticeable hair growth in androgenetic alopecia patients by three months and increased hair density after six months, with some experiencing mild side effects such as postural hypotension and donor site discomfort.

This study developed a new finasteride release system using chitosan-based nanoniosomes, observing that 70% of the drug was released over ten days in vitro, suggesting potential for prostate cancer prevention.

This study reported that a novel ionic liquid delivery system combining ferulic acid and finasteride enhanced the solubility, skin permeation, and effectiveness in promoting hair regrowth in androgenetic alopecia mice, suggesting an improved topical treatment approach.

In this study, induction nab-paclitaxel plus cisplatin, combined with nimotuzumab and IMRT, followed by S-1 adjuvant chemotherapy, showed excellent survival benefits with tolerable toxicities for stage N3 nasopharyngeal carcinoma patients.

In this study, deleting the transcriptional pause factor Nelfb in mouse preadipocyte lineages led to defective dermal fat formation and lethal outcomes, while interventions targeting Pparg could rescue adipocyte differentiation and promote dermal white adipose tissue formation, underscoring Nelfb's critical role in adipogenesis.

This study reported that frontal fibrosing alopecia predominantly affects postmenopausal women and identified potential risk factors like frequent β-blocker use and sunscreen application, indicating the need for further research.

This study observed that using a 1064 nm Nd: YAG laser may stabilize hair loss and promote new growth in some females with frontal fibrosing alopecia, though individual results varied.

This study revealed that tofacitinib may inhibit CD8⁺ T cell infiltration in alopecia areata by modulating the linoleic acid metabolism-Mg²⁺ pathway, providing new insights for potential treatments and diagnosis.

The article in Dermatologic Therapy discusses clinical experiences with using tofacitinib to treat alopecia areata in 63 patients, but no specific results are reported in the abstract.

This study found that 23.2% of surveyed dermatologists in Saudi Arabia prescribe Tofacitinib for alopecia areata, with 72.4% reporting its effectiveness, while 47.7% cited unavailability as the main reason for not prescribing.

This study found that N-acetyl-glucosamine-loaded nanostructured lipid carriers showed promise for skin lightening in healthy volunteers by reducing melanin distribution.

This study of fifty female patients with frontal fibrosing alopecia in Egypt found that it is a complex condition with no definitive treatment, as it often co-occurs with lichen planus and thyroid issues.

This study found that serum FABP4 levels were significantly higher in alopecia areata patients compared to healthy controls and may correlate with disease severity.

This case report describes a 21-year-old woman with circumscribed alopecia areata incognita, who experienced a sustained positive response to treatment with oral tofacitinib after conventional treatments frequently failed to provide lasting effects.

This abstract describes frontal fibrosing alopecia, a type of cicatricial alopecia identified in post-menopausal women, and reports no new clinical findings.

This study found that a bioorthogonal microneedle patch delivering AAV-aFGF effectively improved hair follicle regeneration and sustained hair growth in murine alopecia models compared to other methods.

In this retrospective analysis, the authors reported that off-label tofacitinib treatment in 35 alopecia areata patients demonstrated safety, with no serious adverse events, and effectiveness, with 83.9% showing significant scalp regrowth and 32.3% achieving near total or total regrowth.

In this report, NICE has approved ritlecitinib, an oral kinase inhibitor, as the first recommended treatment for severe alopecia areata in individuals aged 12 and older.

This study developed a new spectrophotometric method to accurately measure finasteride levels in pharmaceutical formulations using a reaction with NBD-CL.

This study suggests that the NCSTN knockout mouse could serve as an HS animal model, with tamoxifen potentially used for gene deletion in mice.

In this study, tofacitinib showed promising efficacy and safety for biologic-naïve elderly patients with moderate-to-severe ulcerative colitis, achieving steroid-free remission and clinical response over 52 weeks.